UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Intratumoral Estrogen Disposition in Breast Cancer

Clinical cancer research, 2010-03, Vol.16 (6), p.1790-1801

2010

Volltextzugriff (PDF)

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer

NMR in biomedicine, 2012-09, Vol.25 (9), p.1033-1042

2012

Volltextzugriff (PDF)

Vascular proliferation is a prognostic factor in breast cancer

Breast cancer research and treatment, 2012-06, Vol.133 (2), p.501-510

2012

Volltextzugriff (PDF)

Long-Term Follow-Up of the Intergroup Exemestane Study

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2507-2514

2017

Volltextzugriff (PDF)

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

Breast cancer research and treatment, 2001-05, Vol.67 (2), p.111-116

2001

Volltextzugriff (PDF)

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Journal of clinical oncology, 2012-03, Vol.30 (7), p.709-717

2012

Volltextzugriff (PDF)

Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status

Journal of steroid biochemistry and molecular biology, 2010-02, Vol.118 (4), p.237-241

2010

Volltextzugriff (PDF)

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2444-2447

2006

Volltextzugriff (PDF)

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

NMR in biomedicine, 2012-02, Vol.25 (2), p.369-378

2012

Volltextzugriff (PDF)

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Acta oncologica, 2014-10, Vol.53 (10), p.1347-1355

2014

Volltextzugriff (PDF)

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells

BMC cell biology, 2017-04, Vol.18 (1), p.17

2017

Volltextzugriff (PDF)

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

Biochimica et biophysica acta, 2013-03, Vol.1830 (3), p.2790-2797

2013

Volltextzugriff (PDF)

Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors

BMC cancer, 2013-10, Vol.13 (1), p.456-456, Article 456

2013

Volltextzugriff (PDF)

Aromatase inhibitors—Socioeconomical issues

Journal of steroid biochemistry and molecular biology, 2007-08, Vol.106 (1), p.55-61

2007

Volltextzugriff (PDF)

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers

Molecular cancer, 2010-07, Vol.9 (1), p.173-173, Article 173

2010

Volltextzugriff (PDF)

Aromatase inhibitors in the treatment of early and advanced breast cancer

Acta oncologica, 2005-01, Vol.44 (1), p.23-31

2005

Volltextzugriff (PDF)

Aromatase inhibitors and inactivators for breast cancer therapy

Drugs & aging, 2002, Vol.19 (4), p.277-298

LØNNING, Per E

2002

Volltextzugriff (PDF)

Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma

Cancer, 1999-02, Vol.85 (4), p.891-898

1999

Volltextzugriff (PDF)

Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment

Acta oncologica, 1998, Vol.37 (4), p.365-368

Helge Haarstad, Per E. Lønning, Stein Gundersen, Erik Wist, Nils Raabe, Stener Kvinnsland

1998

Volltextzugriff (PDF)

Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer

International journal of cancer, 1997-02, Vol.74 (1), p.138-140

1997

Volltextzugriff (PDF)

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer

Cancer research (Chicago, Ill.), 2001-03, Vol.61 (6), p.2505-2512

2001

Volltextzugriff (PDF)

Cell-type-specific responses to chemotherapeutics in breast cancer

Cancer research (Chicago, Ill.), 2004-06, Vol.64 (12), p.4218-4226

2004

Volltextzugriff (PDF)

Aromatase Inhibition: Translation into a Successful Therapeutic Approach

Clinical cancer research, 2005-04, Vol.11 (8), p.2809-2821

2005

Volltextzugriff (PDF)

TP53 Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer

Clinical cancer research, 2003-11, Vol.9 (15), p.5582-5588

2003

Volltextzugriff (PDF)

Influence of Neoadjuvant Anastrozole (Arimidex) on Intratumoral Estrogen Levels and Proliferation Markers in Patients with Locally Advanced Breast Cancer

Clinical cancer research, 2001-05, Vol.7 (5), p.1230-1236

2001

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

ThemaBreast Neoplasms - Pathology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(33)

Sprache

Englisch
(33)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Intratumoral Estrogen Disposition in Breast Cancer

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer

Vascular proliferation is a prognostic factor in breast cancer

Long-Term Follow-Up of the Intergroup Exemestane Study

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

Disease-Related Outcomes With Long-Term Follow-Up: An Updated Analysis of the Intergroup Exemestane Study

Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status

Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling

TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy

Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors

Aromatase inhibitors—Socioeconomical issues

Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers

Aromatase inhibitors in the treatment of early and advanced breast cancer

Aromatase inhibitors and inactivators for breast cancer therapy

Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma

Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment

Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer

Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer

Cell-type-specific responses to chemotherapeutics in breast cancer

Aromatase Inhibition: Translation into a Successful Therapeutic Approach

TP53 Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer

Influence of Neoadjuvant Anastrozole (Arimidex) on Intratumoral Estrogen Levels and Proliferation Markers in Patients with Locally Advanced Breast Cancer

Aktive Filter

Suchergebnisse filtern